Jefferies Raises Price Target on Casey's General Stores (CASY) to $113 Following EPS Miss

BMO Capital Remains Sidelined on Casey's General Stores (CASY) Following 4Q

BMO Capital reiterated a Market Perform rating on Casey's General Stores (NASDAQ: CASY), and raised the price target to $118.00 (from $115.00), following the company's 4Q earnings report. The company also provided goals for 2017. BMO dropped F17 EPS estimates to $5.62 (from $5.75) and F18 estimates to $6.55 (from $6.73).

Analyst Kelly Bania commented, "We continue to believe that CASYs same-store sales outlook remains solid,supported by: 1) the continuation of a robust pipeline for major remodels (in line with F16); 2) +100 each of additional pizza... More

Pre-Open Stock Movers 06/07: (LDRH) (SRPT) (UNFI) Higher; (DRYS) (VRX) (MSTX) Lower (more...)

Today's Pre-Open Stock Movers:

LDR Holding Corporation (NASDAQ: LDRH) 63.4% HIGHER; Zimmer Biomet Holdings, Inc. (NYSE: ZBH), a global leader in musculoskeletal healthcare, and LDR Holding Corporation (NASDAQ: LDRH) (LDR), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, today announced that both Boards of Directors have approved a definitive agreement under which... More

Jefferies Remains Sidelined on Casey's General Stores (CASY) Following Mixed 4Q

Jefferies maintained a Hold rating and $102.00 price target on Casey's General Stores (NASDAQ: CASY) following the company's 4Q earnings report. EBIT came in light at $80M compared to the consensus of $84M. EPS were reported at $1.19 slightly below $1.22 consensus.

Analyst Christopher Mandeville commented,... More

After-Hours Stock Movers 06/06: (SRPT) (UNFI) (ZG) Higher; (DRYS) (MSTX) (ALXN) Lower (more...)

Today's After-Hours Movers:

Sarepta Therapeutics (NASDAQ: SRPT) 26.7% HIGHER; announced that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.

DryShips (NASDAQ:... More

Casey's General Stores (CASY) Misses Q4 EPS by 3c

Casey's General Stores (NASDAQ: CASY) reported Q4 EPS of $1.19, $0.03 worse than the analyst estimate of $1.22. Revenue for the quarter came in at $1.58 billion versus the consensus estimate of $1.57... More

Casey's General Stores (CASY) Shares Remain at Session Lows into Q4 Report

Casey's General Stores (NASDAQ: CASY) shares are trading to session lows ahead of the company's Q4 report.

Analysts see CASY posting Q4 EPS of $1.22 on revenue of $1.57 billion, compared with EPS of $1.57 and revenue of $2.05 billion reported in the same period last year.

Shares are down 1 percent.

Casey's General Stores (CASY) June volatility elevated into Q4 and outlook

Casey's General Stores (NASDAQ: CASY) June call option implied volatility is at 39, July is at 29; compared to its 52-week range of 21 to 40 into the expected release of Q4 results today after the market close.